leadf
logo-loader
viewSUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals appoints CEO Dr Michael Baker as new director

Dr Baker will continue to drive development opportunities for the company.

SUDA Pharmaceuticals Ltd - Suda Pharmaceuticals appoints CEO as new director on the board
Dr Baker’s remuneration will remain unchanged

SUDA Pharmaceuticals Ltd (ASX:SUD) has appointed chief executive officer Dr Michael Baker as a director to the board, effective July 1, 2020.

Dr Baker joined SUDA as the CEO on January 2, 2020, and was tasked with driving the development of the business and will continue to look for new opportunities for the company going forwards.

The remuneration will remain unchanged.

“Key leadership qualities”

Following a handover period to Dr Baker, Paul Hopper will resume his role as non-executive chairman.

Hopper said: “Michael has demonstrated key leadership qualities and we are delighted to welcome Michael onto the board.”

Hopper’s remuneration will reduce from $150,000 to $80,000 per annum.

Cancer and insomnia treatments

SUDA is focused on developing a radically new, first-in-class approach to the treatment of cancer using the drug anagrelide.

The company is also continuing to progress its short-term insomnia treatment, ZolpiMist, for which it is expecting to hear an outcome from its TGA submission in the fourth quarter of 2020.

In addition, the company is developing products in conjunction with its partners, Sanofi (EPA:SAN), Strides Pharma Global, Laboratorios Ordesa, Zelira Therapeutics (ASX:ZLD) and Cann Pharmaceutical Australia.

Quick facts: SUDA Pharmaceuticals Ltd

Price: 0.043 AUD

ASX:SUD
Market: ASX
Market Cap: $13.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval for lead...

Dr Michael Baker, CEO of SUDA Pharmaceuticals Ltd (ASX:SUD), speaks to Proactive's Andrew Scott soon after announcing they've received Therapeutics Goods Administration (TGA) approval for their lead product ZolpiMist for the treatment of short-term insomnia in adults. Baker says it's a...

on 31/7/20

2 min read